122 related articles for article (PubMed ID: 20002159)
21. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
22. Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.
La Rosée P; Jia T; Demehri S; Härtel N; de Vries P; Bonham L; Hollenback D; Singer JW; Melo JV; Druker BJ; Deininger MW
Clin Cancer Res; 2006 Nov; 12(21):6540-6. PubMed ID: 17085669
[TBL] [Abstract][Full Text] [Related]
23. Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta.
Kurosu T; Tsuji K; Kida A; Koyama T; Yamamoto M; Miura O
Oncogene; 2007 May; 26(21):2975-87. PubMed ID: 17130834
[TBL] [Abstract][Full Text] [Related]
24. Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor.
Hirase C; Maeda Y; Takai S; Kanamaru A
Leuk Res; 2009 Mar; 33(3):450-9. PubMed ID: 18783828
[TBL] [Abstract][Full Text] [Related]
25. Rapid detection of phosphotyrosine proteins by flow cytometric analysis in Bcr-Abl-positive cells.
Desplat V; Lagarde V; Belloc F; Chollet C; Leguay T; Pasquet JM; Praloran V; Mahon FX
Cytometry A; 2004 Nov; 62(1):35-45. PubMed ID: 15468123
[TBL] [Abstract][Full Text] [Related]
26. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway.
Noren NK; Foos G; Hauser CA; Pasquale EB
Nat Cell Biol; 2006 Aug; 8(8):815-25. PubMed ID: 16862147
[TBL] [Abstract][Full Text] [Related]
27. BCL2 inhibitor ABT-199 and JNK inhibitor SP600125 exhibit synergistic cytotoxicity against imatinib-resistant Ph+ ALL cells.
Inoue C; Sobue S; Aoyama Y; Mizutani N; Kawamoto Y; Nishizawa Y; Ichihara M; Abe A; Hayakawa F; Suzuki M; Nozawa Y; Murate T
Biochem Biophys Rep; 2018 Sep; 15():69-75. PubMed ID: 30073206
[TBL] [Abstract][Full Text] [Related]
28. Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells.
Yang X; He G; Gong Y; Zheng B; Shi F; Shi R; Yang X
Eur J Haematol; 2014 Feb; 92(2):111-20. PubMed ID: 24112092
[TBL] [Abstract][Full Text] [Related]
29. [Effect of VE-cadherin on sensitivity to Imatinib in Sup-B15 Philadelphia chromosome positive acute lymphoblastic leukemia cells].
Zhang HX; Yan ZL; Song XG; Lü C; Cao J; Li ZY; Zeng LY; Chen C; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):522-6. PubMed ID: 23827112
[TBL] [Abstract][Full Text] [Related]
30. EphB4/ephrinB2 Contributes to Imatinib Resistance in Chronic Myeloid Leukemia Involved in Cytoskeletal Proteins.
Li L; Xu N; Zhang JF; Xu LL; Zhou X; Huang BT; Li YL; Liu XL
Int J Med Sci; 2016; 13(5):365-73. PubMed ID: 27226777
[TBL] [Abstract][Full Text] [Related]
31. Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL.
Leonard JT; Kosaka Y; Malla P; LaTocha D; Lamble A; Hayes-Lattin B; Byrd K; Druker BJ; Tyner JW; Chang BH; Lind E
Blood; 2021 Feb; 137(7):939-944. PubMed ID: 32898857
[TBL] [Abstract][Full Text] [Related]
32. Antileukaemia effect of rapamycin alone or in combination with daunorubicin on Ph+ acute lymphoblastic leukaemia cell line.
Yang X; Lin J; Gong Y; Ma H; Shuai X; Zhou R; Guo Y; Shan Q; He G
Hematol Oncol; 2012 Sep; 30(3):123-30. PubMed ID: 21898527
[TBL] [Abstract][Full Text] [Related]
33. PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma.
Aslam MI; Abraham J; Mansoor A; Druker BJ; Tyner JW; Keller C
Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6383-8. PubMed ID: 24733895
[TBL] [Abstract][Full Text] [Related]
34. EphB4 promotes site-specific metastatic tumor cell dissemination by interacting with endothelial cell-expressed ephrinB2.
Héroult M; Schaffner F; Pfaff D; Prahst C; Kirmse R; Kutschera S; Riedel M; Ludwig T; Vajkoczy P; Graeser R; Augustin HG
Mol Cancer Res; 2010 Oct; 8(10):1297-309. PubMed ID: 21047731
[TBL] [Abstract][Full Text] [Related]
35. Small molecule ErbB inhibitors decrease proliferative signaling and promote apoptosis in philadelphia chromosome-positive acute lymphoblastic leukemia.
Irwin ME; Nelson LD; Santiago-O'Farrill JM; Knouse PD; Miller CP; Palla SL; Siwak DR; Mills GB; Estrov Z; Li S; Kornblau SM; Hughes DP; Chandra J
PLoS One; 2013; 8(8):e70608. PubMed ID: 23936456
[TBL] [Abstract][Full Text] [Related]
36. Niemann-Pick disease type C1(NPC1) is involved in resistance against imatinib in the imatinib-resistant Ph+ acute lymphoblastic leukemia cell line SUP-B15/RI.
Naren D; Wu J; Gong Y; Yan T; Wang K; Xu W; Yang X; Shi F; Shi R
Leuk Res; 2016 Mar; 42():59-67. PubMed ID: 26818574
[TBL] [Abstract][Full Text] [Related]
37. The antileukemia effect of metformin in the Philadelphia chromosome-positive leukemia cell line and patient primary leukemia cell.
Shi R; Lin J; Gong Y; Yan T; Shi F; Yang X; Liu X; Naren D
Anticancer Drugs; 2015 Oct; 26(9):913-22. PubMed ID: 26186064
[TBL] [Abstract][Full Text] [Related]
38. Differential protein expression and oncogenic gene network link tyrosine kinase ephrin B4 receptor to aggressive gastric and gastroesophageal junction cancers.
Liersch-Löhn B; Slavova N; Buhr HJ; Bennani-Baiti IM
Int J Cancer; 2016 Mar; 138(5):1220-31. PubMed ID: 26414866
[TBL] [Abstract][Full Text] [Related]
39. The autophagy induced by curcumin via MEK/ERK pathway plays an early anti-leukemia role in human Philadelphia chromosome-positive acute lymphoblastic leukemia SUP-B15 cells.
Guo Y; Shan QQ; Gong PY; Wang SC
J Cancer Res Ther; 2018; 14(Supplement):S125-S131. PubMed ID: 29578162
[TBL] [Abstract][Full Text] [Related]
40. Quantitative- and phospho-proteomic analysis of the yeast response to the tyrosine kinase inhibitor imatinib to pharmacoproteomics-guided drug line extension.
Dos Santos SC; Mira NP; Moreira AS; Sá-Correia I
OMICS; 2012 Oct; 16(10):537-51. PubMed ID: 22775238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
